BioInvent International AB (publ)
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Renewable Energy Share:100% (All energy consumption, electrical power and district heating/cooling are based on renewable sources)
ESG Focus Areas
- Environmental sustainability
- Social responsibility
- Governance
Environmental Achievements
- Reduced energy consumption over the past 15 years through changes in utility systems.
- Achieved Sweden Green Building Council’s environmental certification with strong performance in indoor environment and resource use.
Social Achievements
- Launched regular Pulse surveys to track work-life balance and employee well-being.
- Established an operationally independent whistleblowing function.
- Maintained low sick leave (1.64%).
- 70/30 gender ratio overall, 64/36 gender ratio in management.
Governance Achievements
- Adopted a Code of Conduct.
- Adopted Bioethics Guidelines.
- Adopted Insider Policy.
- Adopted Anti-bribery Guidelines.
- Adopted Trade Sanctions Guidelines.
- Designed a business continuity plan.
Climate Goals & Targets
Long-term Goals:
- Incorporate sustainability into the entire business concept and increase transparency.
Medium-term Goals:
- Implement new sustainable business strategy to integrate sustainability aspects into business processes and apply by all employees.
Short-term Goals:
- Continue sustainability efforts and initiate work to create action plans for integrating sustainability into business strategy.
Environmental Challenges
- High risk associated with pharmaceutical development, including delays, cost overruns, and ineffective or unsafe products.
- Dependence on external collaborations for clinical trials and commercialization.
- Competition from major pharmaceutical and biotechnology companies.
- Risks related to product liability.
- Dependence on securing adequate financing.
- Fluctuation in revenue from outlicensing agreements.
- Potential challenges in attracting and retaining qualified personnel.
Mitigation Strategies
- Diversified portfolio of clinical development projects.
- Strategic collaborations with pharmaceutical companies.
- Commercial insurance policy for product liability.
- Ongoing liquidity planning and investment in liquid financial instruments.
- Market-based salaries and benefits to attract and retain employees.
- Regular monitoring and evaluation of risks and opportunities.
Supply Chain Management
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Swedish Corporate Governance Code
Certifications: Sweden Green Building Council’s environmental certification
UN Sustainable Development Goals
- Goal 3: Good health and well-being
- Goal 4: Quality education
- Goal 5: Gender equality
- Goal 7: Affordable and clean energy
- Goal 8: Decent work and economic growth
- Goal 12: Responsible consumption and production
BioInvent’s business supports six of the goals of Agenda 2030.
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed